je.st
news
Tag: chmp
CHMP Issues Positive Opinion for Tablet Formulation of Mercks NOXAFIL (posaconazole)
2014-02-28 14:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a new, investigational tablet formulation of NOXAFIL (posaconazole). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: issues
positive
opinion
formulation
MSD Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
2013-07-26 16:16:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Sharpe and Dohme (MSD), known as Merck in the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) review of GLP-1, or incretin-based, therapies, including sitagliptin. Language: English Contact: MSDMedia:Pam Eisele, +1-908-423-5042Michael Close, +1-267-305-1211Investor:Carol Ferguson, +1-908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: type
including
review
statement
Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
2013-07-26 15:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) review of GLP-1, or incretin-based, therapies, including sitagliptin. Language: English Contact: MerckMedia:Pam Eisele, 908-423-5042Mary Elizabeth Blake, 908-423-5550orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: type
including
review
statement
European CHMP Adopts Positive Opinion for Stribild , a Once-Daily,...
2013-03-23 09:15:18| Biotech - Topix.net
Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily, single tablet regimen Stribild for the treatment of HIV-1 infection in adult patients who ... (more)
Tags: positive
opinion
european
adopts